Prostate Cancer Market Driver, Constraints, Key Events, Opportunities and Forecast 2017-2022

Prostate cancer (PC) is a type of cancer that affects the prostate gland of the male reproductive system, and is the most common non-cutaneous malignant cancer in men. Internationally, it is the sixth-largest cancer-related cause of death in men. Those aged over 50 are at the greatest risk of developing PC, with advanced age being the primary risk factor for the disease.

Most cases of PC (95%) are classed as adenocarcinomas, a type of cancer that arises in the cells of glands. Around 4% of cases display transitional cell morphology, and originate from the urothelial lining of the prostatic urethra. In rare cases prostate cancer may present with neuroendocrine morphology, and can arise from neuroendocrine stem cells present in the prostate. PC begins with the conversion of normal semen-secreting prostate gland cells into cancerous cells.

PC is often asymptomatic, which can lead to a lack of diagnosis in the early stages of the disease, rendering treatment less effective once a diagnosis is made. If symptoms are present or if a diagnosis has been made during a physician’s examination, depending on the stage of the disease.

Browse Detail Report With TOC @
http://www.hexareports.com/report/prostate-cancer-heat-map-and-analysis

The PC market consists of therapies for both hormone-sensitive and castration-resistant forms of the disease. The options available for the two forms are notably different, with hormonal therapies used in the hormone-sensitive stage, and chemotherapy or targeted therapies used in the castration-resistant stage. Castration-resistant PC relates to both symptomatic and asymptomatic forms of the disease that no longer respond to hormonal therapy.

Hormonal therapies are widely used across multiple stages of hormone-sensitive disease, and the goal is to halt PC growth stimulated by testosterone. There are two methods used to treat PC through targeting hormones. The first is androgen deprivation therapy (ADT) using gonadotropin releasing hormone (GnRH) agonists and antagonists, and the second is androgen receptor (AR) blockage, using compounds termed anti-androgens.

Request A Sample copy of This Report @
http://www.hexareports.com/report/prostate-cancer-heat-map-and-analysis/request-sample

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the PC market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

* What are the clinical characteristics of currently approved therapies for PC, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them?
* Which novel classes of therapy are expected to emerge in the treatment of PC?
* Which targets do these therapies act upon?
* Which sub-types of patients could potentially benefit from these new products?

Reasons To Buy

1. Understand the current clinical landscape by considering the treatment options available for each patient segment.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Build up a nuanced understanding of the clinical benchmarks set by these products, and considers how the current late-stage pipeline will affect these benchmarks.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Parkinson’s Disease – Heat Map and Analysis -
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis

• Melanoma – Heat Map and Analysis -
http://www.hexareports.com/report/melanoma-heat-map-and-analysis

• Alzheimer’s Disease – Heat Map and Analysis -
http://www.hexareports.com/report/alzheimers-disease-heat-map-and-analysis

Parkinson's Disease Market Regional Consumption and Market Size Forecast by 2022

Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties, and progress in varying stages.

There is currently no cure for PD, with inadequate symptomatic treatments on the market that are suboptimal in terms of efficacy. The most urgent unmet need is the lack of disease-modifying therapies that demonstrate neuroprotective properties to prevent or at least significantly slow neuronal cell death. Significant efforts have been made to develop new treatments to address this need.

The differences between many of these products lie in their mechanisms of action, which must be fully understood by companies looking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the PD market and Phase III pipeline.

Browse Detail Report With TOC @
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population, are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Request A Sample copy of This Report @
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis/request-sample

Scope

* What are the clinical characteristics of currently approved therapies for PD, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
* How will current late-stage molecules affect the market for levodopa therapies, and are they able to yield comparable clinical efficacy results?
* Will the market benefit from any disease-modifying therapies in the near future?

Reasons to buy

1. Understand the current clinical landscape by considering the treatment options available by drug class.
2. Visually compare the currently approved treatments available by drug class, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Prostate Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/prostate-cancer-heat-map-and-analysis

• Dermatology Therapeutics Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/dermatology-therapeutics-drug-development-pipeline-review-2016

• Non-Hodgkin Lymphoma – Heat Map and Analysis -
http://www.hexareports.com/report/non-hodgkin-lymphoma-heat-map-and-analysis

Non-Hodgkin Lymphoma Market Compatitive Landscape and Segmentation Overview by 2017

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of malignancies that originate from lymphoid tissue, with varied clinical and biological features. There were an estimated 385,741 new cases of NHL and 199,630 deaths from NHL worldwide in 2012. NHLs are classified as either indolent (slow-growing) or aggressive (fast-growing). Almost 85% of NHLs are of B-cell origin, while 15% are derived from T/natural killer cells. The small remainder stem from macrophages. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most common types of NHL, representing over 50% of cases.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the NHL market and Phase III pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.

Browse Detail Report With TOC @
http://www.hexareports.com/report/non-hodgkin-lymphoma-heat-map-and-analysis

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Request A Sample copy of This Report @ http://www.hexareports.com/report/non-hodgkin-lymphoma-heat-map-and-analysis/request-sample

Scope

* How is the NHL market landscape expected to change with the uptake of promising novel pipeline products and products that have been recently approved?
* What are the clinical characteristics of currently approved therapies for NHL, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
* What treatment line settings have the greatest unmet need for pipeline drugs to fill?
* Which pipeline drugs have shown the strongest efficacy in clinical trials, and how do these compare to clinical trials of currently marketed drugs?

Reasons to buy

1. Understand the current clinical landscape by considering the treatment options available for each patient segment.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and considers how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them, and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Dermatology Therapeutics Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/dermatology-therapeutics-drug-development-pipeline-review-2016

• Frontier Pharma: Melanoma Therapeutics – Cytokine and Multiple Targeted Small Molecules and mAbs Dominate Pipeline and First-in-Class Innovation -
http://www.hexareports.com/report/frontier-pharma-melanoma-therapeutics-cytokine-and-multiple-targeted-small-molecules

• Global Antibacterial Drugs Market to 2022 – Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance -
http://www.hexareports.com/report/global-antibacterial-drugs-market-to-2022

Antibacterial Drugs Market Research Methodology and Cost Structure analysis 2017-2022

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market. This report considers the key developments in this market, with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis.

Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body’s immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective.

Browse Detail Report With TOC @
http://www.hexareports.com/report/global-antibacterial-drugs-market-to-2022

In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections.
These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.

The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022.

Scope

Antibiotic resistance has caused a surge in the development of antibiotics:
* How big is the antibiotic pipeline?
* How are companies attempting to overcome antibiotic resistance?

Request A Sample copy of This Report @
http://www.hexareports.com/report/global-antibacterial-drugs-market-to-2022/request-sample

The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
* How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
* Will vaccines continue to drive market revenue?

The pipeline contains a range of molecular targets:
* Which molecular targets are most popular in the current pipeline?
* How many late-stage products are active against drug-resistant bacteria?
* What are the commercial prospects for the most promising late-stage pipeline products?

Big Pharma maintains a strong presence within the antibacterial drug market:
* Which of the leading companies are expected to have the highest share of the market by 2022?
* Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
* Which companies rely heavily of revenues derived from antibacterial drugs?

Reasons to buy

1. Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the antibacterial drug market in the context of the overall pipeline and current market landscape. It also includes analysis of the deals landscape, including both licensing deals and co-development deals.
2. Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
3. Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials.
4. Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
5. Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
6. Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products.
7. Assess the licensing and co-development deal landscape for antibacterial therapies.

Browse More Pharmaceutical Related Market Research Reports:

• Frontier Pharma: Hematological Cancers – Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies -
http://www.hexareports.com/report/frontier-pharma-hematological-cancers

• Frontier Pharma: Rheumatoid Arthritis – Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation -
http://www.hexareports.com/report/frontier-pharma-rheumatoid-arthritis

• Frontier Pharma: Glioblastoma Multiforme – Cancer Immunotherapies Dominate First-in-Class Product Innovation -
http://www.hexareports.com/report/frontier-pharma-glioblastoma-multiforme

Melanoma Therapeutics Market Geographical Scope and Manufacture Analysis by 2022

Melanoma is a type of cancer that begins in the melanocytes, often in moles or other pigmented tissues. It most commonly affects the skin, as cutaneous melanoma; however it can also affect other pigmented tissues, such as the eye or intestines, as extracutaneous melanoma. It is the deadliest form of skin cancer and remains one of the most aggressive and treatment-resistant human cancers.

Global prevalence of the disease has risen significantly in the past several decades, primarily due to an increase in exposure to UV light and/or sunlight. This has resulted in an increase in developmental interest with regard to improving disease management, particularly in the advanced metastatic setting.

The emergence over the past decade of novel targeted therapies and therapies that manipulate the immune response has improved treatment options for patients. These new drug classes have been highly commercially successful with blockbuster products that are now well established within the treatment algorithm.

Browse Detail Report With TOC @ http://www.hexareports.com/report/frontier-pharma-melanoma-therapeutics-cytokine-and-multiple-targeted-small-molecules

In spite of these developments, there are still significant unmet needs for both cutaneous and extracutaneous melanoma, and the rationale for investment in first-in-class innovation remains strong. First-in-class products account for a considerable proportion of the melanoma pipeline, which is substantially larger than the current market.

Scope

Rising global prevalence and unmet need have resulted in an increase in developmental interest
* What is the pathophysiology of melanoma?
* How has the emergence of new drug classes in the past decade impacted the treatment algorithm?
* What are the most significant unmet needs within the market?

Request A Sample copy of This Report @ http://www.hexareports.com/report/frontier-pharma-melanoma-therapeutics-cytokine-and-multiple-targeted-small-molecules/request-sample

The melanoma pipeline is large and innovative in comparison with the current market

* Which molecule types and molecular targets are most prominent within the pipeline?
* Which first-in-class targets are most promising?
* How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
* Do melanoma products attract high deal values?
* Which molecule types and molecular targets dominate the deals landscape?
* Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.
2. Visualize the composition of the melanoma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.
3. Analyze the melanoma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within melanoma.
4. Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential.
5. Identify commercial opportunities in the melanoma deals landscape by analyzing trends in licensing and co-development deals and assessing melanoma therapies that are not yet involved in deals, and may be potential investment opportunities.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects -
http://www.hexareports.com/report/frontier-pharma-type-2-diabetes-mellitus-gpcrs-and-protein-kinases-dominate-pipeline

• Diabetes & Obesity Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/diabetes-and-obesity-drug-development-pipeline-review-2016

• Ophthalmology Drug Development Pipeline Review, 2016 -
http://www.hexareports.com/report/ophthalmology-drug-development-pipeline-review-2016

Dermatology Therapeutics Drug Market Key Manufactures, Market Status and Forecast by 2022

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market.

There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.

Browse Detail Report With TOC @ http://www.hexareports.com/report/dermatology-therapeutics-drug-development-pipeline-review-2016

The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type.

A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

* Which companies are the most active within the pipeline for dermatology?
* Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
* To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
* What are the most important R&D milestones and data publications to have happened in this disease area?

Request A Sample copy of This Report @ http://www.hexareports.com/report/dermatology-therapeutics-drug-development-pipeline-review-2016/request-sample

Reasons to buy

1. Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
2. Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
3. Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
4. Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Frontier Pharma: Hepatitis C – Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations -
http://www.hexareports.com/report/frontier-pharma-hepatitis-c

• Global Cancer Immunotherapies Market to 2022 – Immune Checkpoint Inhibitors and Therapeutic Cancer Vaccines to Characterize Increasingly Competitive Market -
http://www.hexareports.com/report/global-cancer-immunotherapies-market-to-2022

• Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline -
http://www.hexareports.com/report/Anti-hypertensive-therapeutics-in-asia-pacific-markets-to-2022

Cystic Fibrosis Market Provide an In-depth Insight of Market 2017-2022

Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body’s epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs and pancreas. Historically therapeutic options have focused heavily on treating the symptoms, but despite being clinically and commercially successful have failed to address the faulty CFTR proteins that cause the disease. This unmet need has led to the development of CFTR modulators.

The treatment algorithm patients receive is likely to consist of an antimicrobial, a mucolytic agent, pancreatic enzymes and possibly a CFTR modulator. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CF market and Phase III or Preregistration stages of the pipeline. These are split along drug class lines, and are therefore reflective of the treatment algorithm.

Browse Detail Report With TOC @
http://www.hexareports.com/report/cystic-fibrosis-heat-map-and-analysis

All safety and efficacy endpoints reported in these trials are displayed. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Request A Sample copy of This Report @
http://www.hexareports.com/report/cystic-fibrosis-heat-map-and-analysis/request-sample

Scope

* To what extent is the CF market landscape expected to change with the introduction of new CFTR modulators?
* What are the clinical characteristics of currently approved therapies for CF, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
* How will current late-stage CFTR modulators affect the market for symptomatic therapies, and are they able to yield comparable clinical efficacy results to Kalydeco?
* How will the influx of tobramycin generics affect the competitive landscape?

Reasons To Buy

1. Understand the current clinical landscape by considering the treatment options available for each patient segment.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Alzheimer’s Disease – Heat Map and Analysis -
http://www.hexareports.com/report/alzheimers-disease-heat-map-and-analysis

• Chronic Obstructive Pulmonary Disease – Heat Map and Analysis -
http://www.hexareports.com/report/chronic-obstructive-pulmonary-disease-heat-map-and-analysis

• Colorectal Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis

Colorectal Cancer Market Import/Export, Supply/Demand and Cost Structure Analysis by 2022

Colorectal cancer (CRC), otherwise known as bowel cancer, is a malignancy originating in the colon (the large intestine) or rectum, both of which are located towards the end of the human gastrointestinal tract. It begins as a benign tumor, which is almost always in the form of a small polyp within the colon or rectum. It rarely occurs in the absence of polyps, although can arise as a result of an inflammatory bowel disease such as Crohn’s disease or ulcerative colitis. CRC was the third most prolific oncological indication with regard to the number of new cases in the US in 2016.

The disease can be divided into two categories based on how advanced it is upon diagnosis. These are early-stage (adjuvant) CRC, which can be treated with surgery, and metastatic (advanced) CRC, which cannot. Therapeutic options differ between the two treatment settings, with therapies for adjuvant CRC aiming to prevent disease re-occurrence and those for advanced conditions aiming to slow disease progression while maintaining the patient’s quality of life.

Browse Detail Report With TOC @
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis

Targeted therapies have already begun to extend the lifespan of metastatic CRC patients compared with chemotherapy-only regimens. However, there remains an unmet need to improve the efficacy of treatment options and extend survival for these patients. Additionally, an unmet need exists for patients with KRAS mutation-positive CRC, for whom certain currently marketed therapies are not recommended.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the CRC market, with additional focus on the late-stage pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

Request A Sample copy of This Report @
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis/request-sample

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

* How is the colorectal cancer market landscape expected to change with regard to therapeutic type, due to promising pipeline therapies?
* What are the clinical characteristics of currently approved therapies for colorectal cancer, in terms of specific safety and efficacy parameters?
* How are clinical safety and efficacy parameters linked to the key unmet needs in this indication?
* How will current late-stage immunotherapeutics affect the colorectal cancer market, and will they be able to satisfy current unmet need with regard to effective therapy options?
* Are future product approvals likely to affect the treatment algorithm significantly?

Reasons to buy


1. Understand the current clinical landscape by considering the treatment options available for early- and late-stage disease.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Ovarian Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/ovarian-cancer-heat-map-and-analysis

• Acute Myeloid Leukemia – Heat Map and Analysis -
http://www.hexareports.com/report/acute-myeloid-leukemia-heat-map-and-analysis

• Rheumatoid Arthritis – Heat Map and Analysis -
http://www.hexareports.com/report/rheumatoid-arthritis-heat-map-and-analysis

Chronic Obstructive Pulmonary Disease Market Provide Production Value and Market Share Analysis 2017-2022

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world.

The disease is characterized by structural changes that result in a narrowing of the small airways, ultimately causing airflow limitation. Both parenchymal destruction – termed emphysema – and small airways disease – referred to as chronic bronchitis – contribute towards these changes, which occur in varying degrees in each patient.

Bronchodilators are established as the main classes of pharmacological maintenance treatment in COPD. They can be administered orally, intravenously or, if preferred, inhaled. The various forms of bronchodilators can be classed as short-acting or long-acting, and both are used in the management of COPD. Although bronchodilators play the key role in the management of COPD symptoms, other forms of treatment.

Browse Detail Report With TOC @ http://www.hexareports.com/report/chronic-obstructive-pulmonary-disease-heat-map-and-analysis

Inhaled corticosteroids (ICS) such as fluticasone propionate and budesonide are used to manage inflammation in both COPD and asthma patients. ICSs bind to the glucocorticoid receptors in the airways, reducing inflammation. In addition, there are signs of more innovative products emerging onto the treatment landscape. An example includes a monoclonal antibody – a class of therapy that has already emerged for asthma – that is in Phase III development.

The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the COPD market and late-stage pipeline. These are split along lines of therapy, and are therefore reflective of the treatment algorithm.

Request A Sample copy of This Report @ http://www.hexareports.com/report/chronic-obstructive-pulmonary-disease-heat-map-and-analysis/request-sample

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and comparison groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Scope

* What are the clinical characteristics of currently approved therapies for COPD, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are most closely linked to them?
* Which novel classes of combination therapy are expected to emerge in the treatment of COPD?
* Which first-in-class products are in development for COPD and what targets do they act upon?
* Which sub-types of patients could potentially benefit from these new products?

Reasons To Buy

1. Understand the current clinical landscape by considering the treatment options available for each patient segment.
2. Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Melanoma – Heat Map and Analysis -
http://www.hexareports.com/report/melanoma-heat-map-and-analysis

• Type 1 Diabetes Mellitus – Heat Map and Analysis -
http://www.hexareports.com/report/type-1-diabetes-mellitus-heat-map-and-analysis

• Type 2 Diabetes Mellitus – Heat Map and Analysis -
http://www.hexareports.com/report/type-2-diabetes-mellitus-heat-map-and-analysis

Alzheimer's Disease Market Growth, Trends, Size and Share Forecast to 2022

Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. The pathological features of AD comprise a complex set of histopathological changes within the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and appear in varying stages. The effects of AD, particularly at an advanced stage, are devastating to patients and their caregivers, and are associated with significant associated healthcare costs.

Current treatments focus on sustaining the patient’s cognitive function, managing behavioural symptoms and slowing down the rate of disease progression. There is currently no cure for AD, and only six symptomatic treatment therapies have been approved, of which one (Cognex) is no longer available in the US. The current market leaders are suboptimal in terms of efficacy, and there is therefore a large unmet need within AD to develop safer and more efficacious treatments.

Browse Detail Report With TOC @
http://www.hexareports.com/report/alzheimers-disease-heat-map-and-analysis

There are numerous differences between many of these products due to their mechanisms of action, and these must be understood fully by companies seeking to position a novel drug in this market.

This tabular heatmap framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed information on all late-stage clinical trial results for products in the AD market and Phase III pipeline. These are split along therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.

Request A Sample copy of This Report @
http://www.hexareports.com/report/alzheimers-disease-heat-map-and-analysis/request-sample

Scope

* What preventative early-stage drugs are generating interest within the AD pipeline?
* Will the current AD market landscape ensure that the first drug with a disease-modifying mechanism of action will become the market leader?
* What are the clinical characteristics of currently approved therapies for AD, in terms of specific safety and efficacy parameters?
* What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?
* How will current late-stage molecules affect the market for AChEIs, and are they able to yield comparable clinical efficacy results?
* With three amyloid inhibitors present in the late-stage pipeline, do they have sufficient differentiating characteristics from previous clinical failures from this class to have an impact on the market?

Reasons To Buy

1. Understand the current clinical landscape by considering the treatment options available by drug class.
2. Visually compare the currently approved treatments available by drug class, based on the most important efficacy and safety parameters tested in clinical trials.
3. Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.
4. Understand the relative strengths and weaknesses of the studies used to gather these data.
5. Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.
6. Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Frontier Pharma: Versatile Innovation in Immunology – Large Therapy Area Pipeline with a High Degree of Repositioning Potential -
http://www.hexareports.com/report/frontier-pharma-versatile-innovation-in-immunology

• Seasonal Influenza Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Elderly Population, Growing Awareness and Launch of Quadrivalent Therapies -
http://www.hexareports.com/report/seasonal-influenza-therapeutics-in-asia-pacific-markets-to-2022

• COPD Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies -
http://www.hexareports.com/report/copd-therapeutics-in-asia-pacific-markets-to-2022

Sacral Nerve Stimulation Market Share, Industry Growth, Trends, Analysis, Overview And Forecasts 2017-2021

Sacral nerve stimulation (SNS) is a medical electrical stimulation therapy that is used to treat long-term bowel control and bladder control symptoms through the modulation of nerves controlling the lower urinary tract and pelvic floor.

The Global Sacral Nerve Stimulation Market to grow at a CAGR of 4.66% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global sacral nerve stimulation market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales, volume, and value of SNS devices.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Browse Detail Report With TOC @
http://www.hexareports.com/report/global-sacral-nerve-stimulation-market-2017-2021

Global Sacral Nerve Stimulation Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Medtronic

Other prominent vendors
• Axonics Modulation Technologies
• Nuvectra

Market driver
• Increasing R&D efforts by companies in SNS market
• For a full, detailed list, view our report

Request A Sample copy of This Report @ http://www.hexareports.com/report/global-sacral-nerve-stimulation-market-2017-2021/request-sample

Market challenge
• Unfavorable reimbursement scenario for SNS procedures
• For a full, detailed list, view our report

Market trend
• O-arm guided navigation in patients with partial sacral agenesis
• For a full, detailed list, view our report

Key questions answered in this report
1. What will the market size be in 2021 and what will the growth rate be?
2. What are the key market trends?
3. What is driving this market?
4. What are the challenges to market growth?
5. Who are the key vendors in this market space?
6. What are the market opportunities and threats faced by the key vendors?
7. What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Browse More Healthcare Related Market Research Reports:

Global ENT Endoscopic and Bronchoscopic Devices Market 2017-2021 –
http://www.hexareports.com/report/global-ent-endoscopic-and-bronchoscopic-devices-market-2017-2021

Global MRI Systems Market 2017-2021 –
http://www.hexareports.com/report/global-mri-systems-market-2017-2021

Global Patient Monitoring Equipment Market 2017-2021 –
http://www.hexareports.com/report/global-patient-monitoring-equipment-market-2017-2021